Susquehanna International Group’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-13,987
| Closed | -$93.5K | – | 13534 |
|
|
2025
Q4 | $93.5K | Buy |
13,987
+5,552
| +66% | +$32.9K | ﹤0.01% | 11489 |
|
|
2025
Q3 | $37K | Sell |
8,435
-5,611
| -40% | -$26.6K | ﹤0.01% | 11935 |
|
|
2025
Q2 | $62.3K | Buy |
14,046
+7,765
| +124% | +$32.4K | ﹤0.01% | 12044 |
|
|
2025
Q1 | $35.6K | Buy |
6,281
+2,735
| +77% | +$35K | ﹤0.01% | 11969 |
|
|
2024
Q4 | $74.8K | Buy |
+3,546
| New | +$81.4K | ﹤0.01% | 11505 |
|
|
2024
Q1 | – | Sell |
-2,005
| Closed | -$107K | – | 12623 |
|
|
2023
Q4 | $107K | Buy |
+2,005
| New | +$90.5K | ﹤0.01% | 11268 |
|
|
2023
Q3 | – | Sell |
-2,078
| Closed | -$95.9K | – | 12379 |
|
|
2023
Q2 | $114K | Buy |
2,078
+227
| +12% | +$12.5K | ﹤0.01% | 10854 |
|
|
2023
Q1 | $77.8K | Buy |
1,851
+446
| +32% | +$13.2K | ﹤0.01% | 11451 |
|
|
2022
Q4 | $38.9K | Buy |
+1,405
| New | +$34.6K | ﹤0.01% | 11526 |
|
|
2022
Q3 | – | Sell |
-2,299
| Closed | -$83K | – | 13557 |
|
|
2022
Q2 | $83K | Buy |
+2,299
| New | +$104K | ﹤0.01% | 11640 |
|
|
2022
Q1 | – | Sell |
-2,306
| Closed | -$163K | – | 13395 |
|
|
2021
Q4 | $163K | Sell |
2,306
-136
| -6% | -$9.67K | ﹤0.01% | 11694 |
|
|
2021
Q3 | $170K | Buy |
2,442
+96
| +4% | +$7.64K | ﹤0.01% | 11666 |
|
|
2021
Q2 | $195K | Buy |
2,346
+763
| +48% | +$54K | ﹤0.01% | 11628 |
|
|
2021
Q1 | $86K | Buy |
+1,583
| New | +$77K | ﹤0.01% | 11907 |
|
|
2020
Q3 | – | Sell |
-6,600
| Closed | -$205K | – | 10769 |
|
|
2020
Q2 | $205K | Buy |
6,600
+4,405
| +201% | +$119K | ﹤0.01% | 8999 |
|
|
2020
Q1 | $49K | Buy |
+2,195
| New | +$59.5K | ﹤0.01% | 9692 |
|
|
2019
Q3 | – | Sell |
-1,681
| Closed | -$34K | – | 10425 |
|
|
2019
Q2 | $34K | Buy |
+1,681
| New | +$49.2K | ﹤0.01% | 9917 |
|
|
2018
Q2 | – | Sell |
-7,661
| Closed | -$383K | – | 9908 |
|
|
2018
Q1 | $383K | Buy |
+7,661
| New | +$343K | ﹤0.01% | 7179 |
|
|
2015
Q2 | – | Sell |
-1,002
| Closed | -$58K | – | 10225 |
|
|
2015
Q1 | $58K | Buy |
+1,002
| New | +$53.8K | ﹤0.01% | 9123 |
|
|
2014
Q3 | – | Sell |
-1,413
| Closed | -$64K | – | 9624 |
|
|
2014
Q2 | $64K | Buy |
+1,413
| New | +$59.4K | ﹤0.01% | 9552 |
|
|
2014
Q1 | – | Sell |
-3,876
| Closed | -$182K | – | 9095 |
|
|
2013
Q4 | $182K | Sell |
3,876
-4,598
| -54% | -$201K | ﹤0.01% | 8337 |
|
|
2013
Q3 | $338K | Buy |
+8,474
| New | +$333K | ﹤0.01% | 7035 |
|
Other funds holding HBIO
WCM
VCM
CCM
MIM
NCNMGF
Susquehanna International Group's HBIO Position: Q1 2026 in Review
Susquehanna International Group sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 13,987 shares — an estimated $93.5K sold.
Susquehanna International Group first reported a position in HBIO in Q3 2013 and held it in 22 quarters. The position peaked at $383K in Q1 2018. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.
- Susquehanna International Group reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
- Susquehanna International Group sold 13,987 Harvard Bioscience shares in Q1 2026, an estimated $93.5K.
- Susquehanna International Group first reported a position in Harvard Bioscience in Q3 2013 and held it in 22 quarters.
- Susquehanna International Group's Harvard Bioscience position peaked at $383K in Q1 2018.
- 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.